comprehensive -WSS

comprehensive

author：knowledge 2025-09-29 04:23:12 - browse：38971

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Lawmakers consider Medicare pay reforms for doctors

WSS

STAT Summit: How a Chicago ER doctor tackles gun violence

Independent physicians launch a new lobbying group

STAT Summit: GSK CEO on pharma giant's new direction

The surgeon had a dilemma only a Nazi medical text could resolve

FDA struggles to regulate food additives, sometimes for decades

UnitedHealth’s board chair also owns a personal investment firm

focus

comprehensive

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

First Opinion Podcast: Long Covid needs a new approach

Apple is now the first public company to be valued at $3 trillion

NIH director takes cautious approach to Biden drug pricing priority

Drug repurposing or repositioning? The language matters

Parkinson’s finding may lead to tests and, someday, treatments

Peter Hotez and the public health issue of online harassment

Senate committee scrutinizes Medicare Advantage brokers

Hepatitis C has a cure — but many Americans still lack access to it

FDA warns J&J's Abiomed: We will regulate your software

leisure time

First Opinion Podcast: Long Covid needs a new approach

Impact of Dobbs ruling felt at reproductive medicine meeting

NIH confirmation hearing shows politicization of research

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The EU Joint Clinical Assessment needs to live up to its promise

AI generated plenty of interest at JPM but not a lot of trust

explore

entertainment

leisure time

hotspot